Building & Running a Theranostics Program¹⁷⁷Lu · ²²⁵Ac · ¹³¹I

Quick Answer

Standing up a radioligand-therapy (RPT) service is as much an operational project as a clinical one, and the gap between "we can read a PSMA PET" and "we run a theranostics program" is where most centers stall. Four pillars have to be in place: a facility (a shielded administration space, a hot lab with a fume hood/dose calibrator/waste decay storage), a radioactive-materials license with a named authorized user (AU) and radiation safety officer (RSO) covering the specific radionuclides and use (NRC 10 CFR 35.300 written-directive therapy, plus 35.396 for parenteral therapies), a team (nuclear physician/AU, nuclear medicine technologists, an on-site or consulting radiopharmacist and medical physicist, and infusion nursing), and a workflow that carries a patient from referral through eligibility imaging, consent, treatment, post-therapy imaging/dosimetry, and toxicity follow-up. Most current β-emitter therapies (¹⁷⁷Lu-PSMA, ¹⁷⁷Lu-DOTATATE) are given outpatient; the program design, scheduling, supply logistics, and reimbursement pathway determine whether it is sustainable.

The facility

At minimum an RPT service needs a dedicated administration room (shielded as required, private, with spill-control surfaces and a nearby patient restroom managed for radioactive waste), a hot lab for receipt/assay/preparation (dose calibrator, L-block/syringe shields, fume hood or containment for any manipulation, contamination monitoring), and decay-in-storage for radioactive waste. Room and shielding requirements scale with the isotope: ¹³¹I (high-energy γ, historically inpatient at higher activities) differs sharply from ¹⁷⁷Lu (lower-energy β/γ, outpatient). Signage, surveys, and area monitoring follow the license conditions.

License, roles & regulation

You cannot administer therapy without a radioactive-materials license (NRC or an Agreement State) that lists the radionuclide, chemical form, and use. Key roles:

Every therapy requires a written directive (patient, radionuclide, activity, route) before administration, and a time-out verifying it — the therapy-side analog of surgical safety checks.

The clinical workflow

A durable program runs a repeatable pathway, not ad-hoc treatments:

1. Referral & eligibility — the theranostic companion scan (PSMA PET for Lu-PSMA; SSTR/DOTATATE PET for PRRT) confirms target expression; labs, prior-therapy review, and organ reserve are checked.
2. Multidisciplinary tumor board — oncology, urology/endocrinology, nuclear medicine, and radiation oncology align on line of therapy and sequencing.
3. Consent & counseling — efficacy expectations, side effects, and radiation-safety precautions for the patient and household.
4. Treatment day — written directive/time-out, administration, supportive care (e.g. amino-acid renal protection for PRRT), and monitoring.
5. Post-therapy imaging / dosimetry — post-treatment SPECT/CT confirms distribution and can support dosimetry-guided dosing.
6. Follow-up — per-cycle labs and toxicity surveillance; response assessment on companion PET.

Scheduling, supply & reimbursement

RPT logistics are dominated by radioactive decay: agents are made to order, ship on a fixed calendar, and cannot be stockpiled, so a no-show or a lab that disqualifies a patient on treatment day wastes an expensive, perishable dose. Programs build slack and confirmation calls into scheduling. On the business side, most agents follow a buy-and-bill model (the site purchases the drug and bills a J-code plus an administration code); newer therapies may carry transitional pass-through / NTAP status affecting hospital reimbursement. Sustainable throughput depends on aligning referral volume, isotope delivery cadence, chair/room time, and payer authorization.

High-Yield Pearls

• Four pillars: facility, license/AU-RSO, team, workflow — clinical skill alone doesn't make a program.
• Every therapy needs a written directive (10 CFR 35.300/.396) and a verifying time-out.
• Most current β-therapies (¹⁷⁷Lu-PSMA, ¹⁷⁷Lu-DOTATATE) are outpatient; ¹³¹I logistics differ (energy/activity).
• The companion PET confirms target expression before treatment — it is the eligibility gate, not a formality.
• Doses are perishable and made-to-order — scheduling discipline protects an expensive resource.

Common Pitfalls

• Treating without a companion scan confirming target expression.
• Under-resourcing the RSO/physics side — release calculations and surveys are license obligations, not optional.
• Ad-hoc scheduling that wastes perishable doses on same-day disqualifications or no-shows.
• No tumor board — sequencing decisions made in isolation from oncology.

Related Pages

• Overview: Theranostics — Overview; safety: Radiation safety & patient release; toxicity: Radionuclide therapy — eligibility & toxicity monitoring.

Self-Check

Key References

• NRC 10 CFR Part 35 (medical use of byproduct material) — authorized-user training/experience and written-directive requirements.
• SNMMI/EANM practice guidance on establishing and operating radioligand-therapy services; reimbursement and buy-and-bill overviews.